ArticleMaterials today. Bio2025
Nerve growth factor-loaded biomimetic prussian blue nanocomplexes for reversing osteoporosis via promoting osteoblast precursor cell proliferation and differentiation.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The potential role and research progress of the gut microbiota-NGF axis in postmenopausal bone homeostasis imbalance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fundamental issue of osteoporosis (OP) is osteoblast decrease due to oxidative stress and the subsequent disruption of the osteogenic and osteoclastic dynamic balance. How to promote the proliferation and osteogenic differentiation of osteoblast precursor cells (MC3T3-E1) in an oxidative microenvironment is a great challenge for improving OP. In this study, Prussian blue nanoparticles (PB NPs) were initially functionalized with a polydopamine (PDA) coating. Nerve growth factor (NGF) was subsequently immobilized on the PDA layer, followed by the hybrid membrane coating composed of red blood cell membrane (RBCm) and MC3T3-E1 cell membrane (MC3T3m), thereby constructing a biomimetic Prussian blue nanocomplex loaded with NGF (MPDN NPs). In vitro studies have shown that the nanodrug restored the impaired proliferation viability of MC3T3-E1 cells and inhibit their apoptosis by scavenging reactive oxygen species (ROS), and further cooperate with NGF to promote osteogenic differentiation. In vivo studies have demonstrated that the nanodrug significantly inhibited bone loss and promote bone regeneration in osteoporotic mice. Moreover, this nanodrug with excellent safety both in vitro and in vivo showed the long half-life in the bloodstream and high accumulation in the bone. In summary, this strategy addresses the fundamental issue of decreased osteoblast in OP and offers a novel approach for preventing and treating OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.